ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1563737
This article is part of the Research TopicOpportunities and Challenges of Head and Neck Cancer Treatment in the Era of Immune Checkpoint InhibitorsView all 12 articles
Neoadjuvant immunochemotherapy versus neoadjuvant immunoradiotherapy in locally advanced oral squamous cell carcinoma
Provisionally accepted
- Henan Provincial Cancer Hospital, Zhengzhou, Henan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To juxtapose the efficacy and safety profiles of neoadjuvant immunochemotherapy (NAIC) and neoadjuvant immunoradiotherapy (NAIR) in the management of locally advanced oral squamous cell carcinoma (SCC).Methods: A retrospective analysis of prospectively gathered data was conducted. The study evaluated the impact of NAIC versus NAIR on various parameters, including pathologic complete response (pCR), major pathologic response (mPR), clinical to pathological downstaging, surgical site infection, quality of life, pathologic adverse features, and prognostic outcomes.Results: The study encompassed a total of 120 patients, with 73 undergoing NAIC. The pCR and mPR rates in the NAIR group were 25.5% and 63.8%, respectively, closely mirroring the 31.5% and 69.9% observed in the NAIC cohort. A propensity for clinical to pathological downstaging and a reduced incidence of pathologic adverse features was noted in the NAIC population. However, both groups exhibited similar distributions in surgical site infection rates, quality of life metrics, grade 3/4 adverse events, and overall survival. In the Cox proportional hazards model, patients receiving NAIC demonstrated a hazard ratio of 0.87 (95% confidence interval: 0.65-0.98) for 3-year locoregional control, relative to the NAIR group.Conclusion: In the context of locally advanced oral SCC, both NAIC and NAIR exhibited robust efficacy and safety profiles. Nevertheless, NAIC provided superior locoregional control compared to NAIR, thereby emerging as the more favorable initial therapeutic option over NAIR.
Keywords: Neoadjuvant immunochemotherapy, neoadjuvant immunoradiotherapy, oral squamous cell carcinoma, Pathologic complete response, Quality of Life
Received: 20 Jan 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Lu, Ding, Wang and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yufei Lu, Henan Provincial Cancer Hospital, Zhengzhou, 450000, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.